Biomarkers of drug-induced vascular injury

Toxicology and Applied Pharmacology

Volumn 207, Issue 2 SUPPL., 2005, Pages 441-445

  Brott, D ^a,b   Gould, S ^a   Jones, H ^a   Schofield, J ^a   Prior, H ^a   Valentin, J P ^a   Bjurstrom, S ^c   Kenne, K ^c   Schuppe Koistinen, I ^c   Katein, A ^a   Foster Brown, L ^a   Betton, G ^a   Richardson, R ^b   Evans, G ^a   Louden, C ^a,b  

^a ASTRAZENECA   (United Kingdom)

^b UNIVERSITY OF MICHIGAN   (United States)

^c ASTRAZENECA R AND D   (Sweden)

Author keywords

Caveolin 1; Drug induced vascular injury; Von Willebrand factor; Von Willebrand factor propeptide

Indexed keywords

3 (2 CARBOXYMETHOXY 4 METHOXYPHENYL) 1 (3,4 METHYLENEDIOXYPHENYL) 5 PROPOXY 2 INDANCARBOXYLIC ACID; ACTIN; ALPHA ACTIN; BIOLOGICAL MARKER; BOSENTAN; CAVEOLIN 1; CYCLIC AMP; ENDOTHELIN RECEPTOR ANTAGONIST; FENOLDOPAM; MINOXIDIL; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; THEOPHYLLINE; VON WILLEBRAND FACTOR;

ADVENTITIA; BLOOD PRESSURE; BLOOD VESSEL INJURY; BLOOD VESSEL TONE; CELL ACTIVATION; CELL DAMAGE; CELL SURFACE; CELL TYPE; CONFERENCE PAPER; CORONARY ARTERY BLOOD FLOW; DISEASE COURSE; DISEASE SEVERITY; DRUG SAFETY; ENDOTHELIUM CELL; HEART ARRHYTHMIA; HEART RATE; HEMODYNAMIC MONITORING; HUMAN; HYPOTENSION; IMMUNOHISTOCHEMISTRY; INCIDENCE; MOLECULAR MECHANICS; NONHUMAN; PATHOGENESIS; PATIENT MONITORING; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN SECRETION; RISK ASSESSMENT; SHEAR STRESS; SMOOTH MUSCLE FIBER; TACHYCARDIA; THROMBOCYTE AGGREGATION; VASODILATATION;

CANIS FAMILIARIS;

EID: 24644495330     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2005.04.028     Document Type: Conference Paper

References (16)

1. M.A. Albassam, A.L. Metz, R.E. Potoczak, K.P. Gallagher, S. Haleen, H. Hallak, and E.J. McGuire Studies on coronary arteriopathy in dogs following administration of CI-1020, an endothelin A receptor antagonist Toxicol. Pathol. 29 2001 277 284
2. P. Dogterom, G. Zbinden, and G.K. Reznik Cardiotoxicity of vasodilators and positive inotropic/vasodilating drugs in dogs: an overview Crit. Rev. Toxicol. 22 1992 203 241
3. M.S. Goligorsky, H. Li, S. Brodsky, and J. Chen Relationships between caveolae and eNOS: everything in proximity and the proximity of everything Am. J. Physiol. Renal Physiol. 283 2002 F1 F10
4. H.B. Jones, A. Macpherson, G.R. Betton, A.S. Davis, R. Siddall, and P. Greaves Endothelin antagonist-induced coronary and systemic arteritis in the beagle dog Toxicol. Pathol. 31 2003 263 272
5. C. Louden, and D.G. Morgan Pathology and pathophysiology of drug-induced arterial injury in laboratory animals and its implications on the evaluation of novel chemical entities for human clinical trials Pharmacol. Toxicol. 89 2001 158 170
6. C. Louden, P. Nambi, C. Branch, K. Gossett, M. Pullen, S. Eustis, and H. Solleveld Coronary arterial lesions in dogs treated with an endothelial receptor antagonist J. Cardiovasc. Pharmacol. 31 Suppl. 1 1998 S384 S385
7. C.S. Louden, P. Nambi, M.A. Pullen, R.A. Thomas, L.A. Tierney, H.A. Solleveld, and L.W. Schwartz Endothelin receptor subtype distribution predisposes coronary arteries to damage Am. J. Pathol. 157 2000 123 134
8. G.M. Mesfin, G.G. Shawaryn, and M.J. Higgins Cardiovascular alterations in dogs treated with hydralazine Toxicol. Pathol. 15 1987 405 416
9. G.M. Mesfin, F.G. Robinson, M.J. Higgins, W.-Z. Zhong, and D.W. DuCharme The pharmacologic basis of the cardiovascular toxicity of minoxidil in the dog Toxicol. Pathol. 23 1995 498 505
10. S.J. Newsholme, D.T. Thudium, K.A. Gossett, E.S. Watson, and L.W. Schwartz Evaluation of plasma von Willebrand factor as a biomarker for acute arterial damage in rats Toxicol. Pathol. 28 2000 688 693
11. J.T. Sobota Review of cardiovascular findings in humans treated with minoxidil Toxicol. Pathol. 17 1989 193 201
12. J.T. Sobota, W.B. Martin, R.G. Carlson, and E.S. Feenstra Minoxidil: right atrial cardiac pathology in animals and man Circulation 62 1980 376 387
13. C. Schwencke, M. Yamamoto, S. Okumura, Y. Toya, S.J. Kim, and Y. Ishikawa Compartmentation of cyclic adenosine 3′,5′-monophosphate signaling in caveolae Mol. Endocrinol. 13 1999 1061 1070
14. L.A. Sporn, V.J. Marder, and D.D. Wagner Differing polarity of the constitutive and regulated secretory pathways for von Willebrand factor in endothelial cells J. Cell Biol. 108 1989 1283 1289
15. H.V. Stel, K.S. Sakariassen, P.G. de Groot, J.A. van Mourik, and J.J. Sixma Von Willebrand factor in the vessel wall mediates platelet adherence Blood 65 1985 85 90
16. M. Stephan-Gueldner, and A. Inomata Coronary arterial lesions induced by endothelin antagonists Toxicol. Lett. 112-113 2000 531 535